Phase 2a data showed a single intranasal dose of BPL-003 produced a rapid and durable antidepressant response in adults with treatment-resistant depression who remained on stable SSRI therapy. The positive early clinical readout de-risks AtaiBeckley’s pipeline and is likely to drive a modest, company-specific stock move as the program advances to larger trials.
Phase 2a data showed a single intranasal dose of BPL-003 produced a rapid and durable antidepressant response in adults with treatment-resistant depression who remained on stable SSRI therapy. The positive early clinical readout de-risks AtaiBeckley’s pipeline and is likely to drive a modest, company-specific stock move as the program advances to larger trials.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
